Long-term cohort study of chronic hepatitis C according to interferon efficacy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 2, 2012, Pages 291-299

  Maruoka, Daisuke ^a   Imazeki, Fumio ^a   Arai, Makoto ^a   Kanda, Tatsuo ^a   Fujiwara, Keiichi ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; Hepatitis C virus; Interferon; Sustained virological response

Indexed keywords

RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CHRONIC LIVER DISEASE; COHORT ANALYSIS; DEATH; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; VIROLOGY;

EID: 84856151318     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06871.x     Document Type: Article

References (36)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005; 5: 558-67.
2. World Health Organization. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral Hepat. 1999; 6: 35-47.
3. Kiyosawa K, Sodeyama T, Tanaka E etal. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-5.
4. Bruix J, Barrera JM, Calvet X etal. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 2: 1004-6.
5. Tong MJ, El-Farra NS, Reikes AR etal. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 1995; 332: 1463-6.
6. Davila JA, Morgan RO, Shaib Y etal. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127: 1372-80.
7. Yoshida H, Shiratori Y, Moriyama M etal. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann. Intern. Med. 1999; 131: 174-81.
8. Cammà C, Giunta M, Andreone P etal. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J. Hepatol. 2001; 34: 593-602.
9. Shiratori Y, Ito Y, Yokosuka O etal. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann. Intern. Med. 2005; 142: 105-14.
10. Huang JF, Yu ML, Lee CM etal. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1386-patient study from Taiwan. Aliment. Pharmacol. Ther. 2007; 25: 1029-37.
11. Kasahara A, Hayashi N, Mochizuki K etal. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998; 27: 1394-402.
12. Imai Y, Kawata S, Tamura S etal. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann. Intern. Med. 1998; 129: 94-9.
13. Yabuuchi I, Imai Y, Kawata S etal. Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma. Liver 2000; 20: 290-5.
14. Kasahara A, Tanaka H, Okanoue T etal. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J. Viral Hepat. 2004; 11: 148-56.
15. Davis GL, Balart LA, Sciff ER etal. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1989; 321: 1501-6.
16. Shindo M, Di Bisceglie AM, Cheung L etal. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann. Intern. Med. 1991; 115: 700-4.
17. Bonis PA, Ioannidis JP, Cappelleri JC etal. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics. Hepatology 1997; 26: 1035-44.
18. Shiratori Y, Imazeki F, Moriyama M etal. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. 2000; 132: 517-24.
19. Desmet VJ, Gerber M, Hoofnagle JH etal. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
20. Kashiwakuma T, Hasegaawa A, Kajita T etal. Detection of hepatitis C virus specific core protein in serum of patients by a sensitive fluorescence enzyme immunoassay (FEIA). J. Immunol. Methods 1996; 190: 79-89.
21. Shiratori Y, Kato N, Yoshida H etal. Sustained viral response is rarely achieved in patients with high viral load of HCV RNA by excessive interferon therapy. Dig. Dis. Sci. 2000; 45: 565-74.
22. Furusyo N, Hayashi J, Kashiwagi K etal. Hepatitis C virus (HCV) RNA level determined by second-generation branched-DNA probeassay as predictor of response to interferon treatment in patients with chronic HCV viremia. Dig. Dis. Sci. 2002; 47: 535-42.
23. Kawai S, Yokosuka O, Imazeki F etal. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level. J. Med. Virol. 2002; 68: 343-51.
24. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K etal. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994; 19: 1347-53.
25. Wai CT, Greenson JK, Fontana RJ etal. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
26. Singal AK, Singh A, Jaganmohan S etal. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin. Gastroenterol. Hepatol. 2010; 8: 192-9.
27. Miyake Y, Iwasaki Y, Yamamoto K. Meta-analysis: reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C. Int. J. Cancer 2010; 127: 989-96.
28. Yu ML, Lin SM, Chuang WL etal. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir. Ther. 2006; 11: 985-94.
29. Shimauchi Y, Tanaka M, Sata M etal. Clinical characteristics of patients in their 40s with HCV antibody-positive hepatocellular carcinoma. Alcohol. Clin. Exp. Res. 2000; 24: 64S-7S.
30. Fujishima T, Ishikawa T, Omata M etal. Age-related comparison of the profiles of patients with hepatocellular carcinoma. Hepatogastroenterology 2006; 53: 913-18.
31. Saneto H, Kobayashi M, Kumada H etal. Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients. J. Gastroenterol. 2008; 43: 975-81.
32. Yamaguchi K, Omagari K, Kinoshita H etal. Development of hepatocellular carcinoma in a patient with chronic hepatitis C after 6years of a sustained and complete response to IFN-alpha. J. Clin. Gastroenterol. 1999; 29: 207-9.
33. Inoue M, Ohhira M, Ohtake T etal. Hepatocellular carcinoma developed in a patient with chronic hepatitis C after the disappearance of hepatitis C virus due to interferon therapy. Hepatogastroenterology 1999; 46: 2554-60.
34. Toyoda H, Kumada T, Honda T etal. Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 2001; 16: 1131-7.
35. Tsuda N, Yuki N, Mochizuki K etal. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J. Med. Virol. 2004; 74: 406-13.
36. Radkowski M, Gallegos-Orozco JF, Jablonska J etal. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41: 106-14.